PASSAGE BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.08 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2025-03-04
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.02, a 86.92% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $7.80.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.08.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.02, a 50.49% decline from fiscal 2021.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $2.06, a 0.96% decline from fiscal 2020.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $2.08, a 103.92% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.08 10-K · filed 2025-03-04 | |||
| 2024-09-30 | $1.08 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $1.08 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $1.02 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $1.02 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $1.02 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $1.02 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $2.06 10-K · filed 2022-03-03 | |||
| 2021-09-30 | $3.06 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $3.91 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $7.80 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | $2.08 10-K · filed 2021-03-03 | |||
| 2020-09-30 | $1.02 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $1.02 10-Q · filed 2020-08-13 | |||
| 2019-12-31 | $1.02 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |